Age group-specific changes in keratinocyte cancer treatment rates in Australia, 2012- 2021: a retrospective cohort study based on MBS claims data.
Carcinoma, keratinocyte
Diagnostic tests and procedures
Population health
Skin neoplasms
Journal
The Medical journal of Australia
ISSN: 1326-5377
Titre abrégé: Med J Aust
Pays: Australia
ID NLM: 0400714
Informations de publication
Date de publication:
29 Apr 2024
29 Apr 2024
Historique:
received:
27
04
2023
accepted:
30
11
2023
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
30
4
2024
Statut:
aheadofprint
Résumé
To examine recent changes in the numbers of Medicare-subsidised keratinocyte cancer excisions, particularly for younger people exposed to primary prevention campaigns since the early 1980s. Retrospective cohort study; analysis of administrative data. Analysis of Medicare Benefits Schedule (MBS) claims data for procedures related to the diagnosis and treatment of keratinocyte cancer in Australia, 2012-2021. Age-standardised rates for MBS-subsidised claims for first surgical squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) excisions, Mohs surgery, surgical excisions of benign lesions, skin biopsies, and cryotherapy or serial curettage of premalignant and malignant lesions, overall, and by sex, state/territory, and age group; average annual percentage change in rate for time intervals determined by joinpoint regression. In men, the age-standardised rate of BCC/SCC excisions increased by 1.9% (95% confidence interval [CI], 1.4-2.4%) per year during 2012-2019 (from 2931 to 3371 per 100 000 men) and then declined by 3.8% (95% CI, 0.5-7.0%) per year during 2019-2021 (to 3152 per 100 000). In women, the age-standardised rate increased by 2.2% (95% CI, 1.7-2.8%) per year during 2012-2019 (from 1798 to 2093 per 100 000 women); the decline to 1967 excisions per 100 000 women in 2021 was not statistically significant. BCC/SCC excision rates declined for men under 55 years of age (by 1.0-3.4% per year) and women under 45 years of age (by 1.7-2.3% per year). Age-standardised biopsy rates increased during 2012-2021 in all age groups (by 2.8-6.9% per year). Rates of MBS-subsidised treatment for keratinocyte cancers increased during 2012-2019, but BCC/SCC treatment rates declined among younger Australians, who have probably been exposed to less sunlight than earlier generations because of public health interventions and population-wide lifestyle changes related to technology use.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Health and Medical Research Council
ID : APP1063061
Organisme : National Health and Medical Research Council
ID : APP1073898
Organisme : National Health and Medical Research Council
ID : APP1155413
Organisme : National Health and Medical Research Council
ID : APP1185416
Informations de copyright
© 2024 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.
Références
Olsen CM, Pandeya N, Green AC, et al. Keratinocyte cancer incidence in Australia: a review of population‐based incidence trends and estimates of lifetime risk. Public Health Res Pract 2022; 32: 3212203.
Australian Institute of Health and Welfare. Disease expenditure in Australia 2019–20 [here: table 5]. Updated 2 Dec 2022. https://www.aihw.gov.au/reports/health‐welfare‐expenditure/disease‐expenditure‐in‐australia‐2019‐20/data (viewed Jan 2023).
Ragaini BS, Blizzard L, Newman L, et al. Temporal trends in the incidence rates of keratinocyte carcinomas from 1978 to 2018 in Tasmania, Australia: a population‐based study. Discov Oncol 2021; 12: 30.
Kwiatkowska M, Ahmed S, Ardern‐Jones M, et al. An updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013–2018. Skin Health Dis 2021; 1: e61.
Stang A, Khil L, Kajüter H, et al. Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents. J Eur Acad Dermatol Venereol 2019; 33 (Suppl 8): 6‐10.
Tokez S, Hollestein L, Louwman M, et al. Incidence of multiple vs first cutaneous squamous cell carcinoma on a nationwide scale and estimation of future incidences of cutaneous squamous cell carcinoma. JAMA Dermatol 2020; 156: 1300‐1306.
Robsahm TE, Helsing P, Veierød MB. Cutaneous squamous cell carcinoma in Norway 1963–2011: increasing incidence and stable mortality. Cancer Med 2015; 4: 472‐480.
Kappelin J, Green AC, Ingvar Å, et al. Incidence and trends of basal cell carcinoma in Sweden: a population‐based registry study. Br J Dermatol 2022; 186: 963‐969.
Adalsteinsson JA, Olafsdottir E, Ratner D, et al. Invasive and in situ squamous cell carcinoma of the skin: a nationwide study in Iceland. Br J Dermatol 2021; 185: 537‐547.
Adalsteinsson JA, Ratner D, Olafsdóttir E, et al. Basal cell carcinoma: an emerging epidemic in women in Iceland. Br J Dermatol 2020; 183: 847‐856.
Aggarwal P, Knabel P, Fleischer AB. United States burden of melanoma and non‐melanoma skin cancer from 1990 to 2019. J Am Acad Dermatol 2021; 85: 388‐395.
Cancer Council Australia. Surgical treatment. In: Clinical practice guidelines for keratinocyte cancer. Oct 2020. https://www.cancer.org.au/clinical‐guidelines/skin‐cancer/keratinocyte‐cancer (viewed Jan 2023).
Thompson BS, Olsen CM, Subramaniam P, et al. Medicare claims data reliably identify treatments for basal cell carcinoma and squamous cell carcinoma: a prospective cohort study. Aust N Z J Public Health 2016; 40: 154‐158.
Olsen CM, Williams PF, Whiteman DC. Turning the tide? Changes in treatment rates for keratinocyte cancers in Australia 2000 through 2011. J Am Acad Dermatol 2014; 71: 21‐26.
Montague M, Borland R, Sinclair C. Slip! Slop! Slap! and SunSmart, 1980–2000: skin cancer control and 20 years of population‐based campaigning. Health Educ Behav 2001; 28: 290‐305.
Australian Department of Health and Ageing. Medical Benefits Schedule book. Operating from 01 January 2012 (D0557). 2011. https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/E137A6BDE8494881CA2585FF000A72FF/$File/201201‐MBS.pdf (viewed Jan 2023).
Australian Department of Health. Medicare Benefits Schedule book. Operating from 1 January 2020 (revised 17 January 2020 to include 36 new items). 2020. https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/8F3FA58ED97DCA35CA2584BE00111151/$File/202001‐MBS%2017Jan2020.pdf (viewed Jan 2023).
Australian Bureau of Statistics. Standard population for use in age‐standardisation statistics. In Australian demographic statistics, Mar 2013 (3101.0). 26 Sept 2013. https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Mar%202013?OpenDocument (viewed Jan 2023).
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335‐351.
Kim HJ, Fay MP, Yu B, et al. Comparability of segmented line regression models. Biometrics 2004; 60: 1005‐1014.
Dinmohamed AG, Visser O, Verhoeven RHA, et al. Fewer cancer diagnoses during the COVID‐19 epidemic in the Netherlands. Lancet Oncol 2020; 21: 750‐751.
Kleemann J, Meissner M, Özistanbullu D, et al. Impact of the Covid‐19 pandemic on melanoma and non‐melanoma skin cancer inpatient treatment in Germany: a nationwide analysis. J Eur Acad Dermatol Venereol 2022; 36: 1766‐1773.
Marson JW, Maner BS, Harding TP, et al. The magnitude of COVID‐19's effect on the timely management of melanoma and nonmelanoma skin cancers. J Am Acad Dermatol 2021; 84: 1100‐1103.
Oakes AH, Boyce K, Patton C, Jain S. Rates of routine cancer screening and diagnosis before vs after the COVID‐19 pandemic. JAMA Oncol 2023; 9: 145‐146.
Iannacone MR, Green AC. Towards skin cancer prevention and early detection: evolution of skin cancer awareness campaigns in Australia. Melanoma Manag 2014; 1: 75‐84.
Tabbakh T, Volkov A, Wakefield M, Dobbinson S. Implementation of the SunSmart program and population sun protection behaviour in Melbourne, Australia: results from cross‐sectional summer surveys from 1987 to 2017. PLoS Med 2019; 16: e1002932.
Czarnecki D. The incidence of melanoma is increasing in the susceptible young Australian population. Acta Derm Venereol 2014; 94: 539‐541.
Staples MP, Elwood M, Burton RC, et al. Non‐melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 2006; 184: 6‐10. https://www.mja.com.au/journal/2006/184/1/non‐melanoma‐skin‐cancer‐australia‐2002‐national‐survey‐and‐trends‐1985
Australian Institute of Health and Welfare. Skin cancer in Australia (Cat. no. CAN 96). 13 July 2016. https://www.aihw.gov.au/reports/cancer/skin‐cancer‐in‐australia (viewed Jan 2023).
Thompson BS, Pandeya, N, Olsen CM, et al. Keratinocyte cancer excisions in Australia: who performs them and associated costs. Australas J Dermatol 2019; 60: 294‐300.